Abstract
Objective To analyze the cost-effectiveness drug economic sense of sequential therapy of levofloxacin in treatment of urinary tract infections,in order to provide reference for the rational use of drugs.Methods From January 2010 to January 2013,160 patients with urinary tract infections were randomly divided into experimental group (80 cases) and control group (80 cases).Patients in experimental group were treated by fleroxacin sequential therapy,and patients in control group were treated by fleroxacin intravenous infusion therapy.The effects of the two groups were observed and the economics of the drug costs between the two groups were evaluated.Results In experimental group,36 cases were cured and effective in 35 cases,the total effective rate was 88.75％ ; In control group,34 cases were cured and effective in 36 cases,the total effective rate was 87.50％.Two hundred and two strains of pathogenic bacteria of urine culture were collected from 160 patients,109 strains of experimental group and 93 strains of control group,respectively.After treatment,98 and 85 strains were cleared,respectively,and the clearance rates were 89.91％ and 91.40％,there was no statistically significant difference between the two groups(P ＞ 0.05).The cost and cost-effectiveness ratio of the experimental group were significantly lower than those of the control group(P ＜ 0.05).Conclusions Sequential therapy of levofloxacin in treatment of urinary tract infections has less cost economics,but the effect is significant,patients are well tolerated.It provide a reference solution for the clinical treatment of urinary tract infections. Key words: Fleroxacin; Sequential therapy; Urinary tract infection; Cost-effectiveness analysis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
